Does this ASX 200 stock’s fall make it a no-brainer buy?

I think Sigma Healthcare Ltd (ASX: SIG) has quietly become one of the more interesting names on the S&P/ASX 200 Index (ASX: XJO).

After completing its merger with Chemist Warehouse last year, the business now represents a scaled, integrated, healthcare and retail pharmacy powerhouse.

And yet, despite that transformation, the share price has pulled back sharply. At around $2.58, Sigma is sitting at a 52-week low and down more than 20% from its recent highs.

That raises an obvious question for investors. Is this a buying opportunity?

A stronger business than before

The first thing to understand is that Sigma today is not the same business it was a few years ago.

The Chemist Warehouse merger has materially changed the earnings profile. The combined group is now benefiting from strong retail sales growth, expanding store networks, and increasing scale advantages across its supply chain.

Its latest half-year result highlighted this clearly. Revenue rose 14.9% to $5.5 billion, while normalised net profit after tax increased 19.2%.

Importantly, this growth is not being driven by one-off factors. Chemist Warehouse has a long track record of strong same-store sales growth, supported by its value proposition and brand strength. That momentum appears to be continuing, with double-digit growth across both domestic and international markets.

At the same time, Sigma is progressing integration and synergy benefits, with a target of $100 million per annum in synergies by FY29.

In other words, the business is getting bigger, more efficient, and more profitable.

A defensive growth profile

One of the reasons Sigma stands out to me is its mix of defensiveness and growth.

Healthcare spending tends to be relatively resilient, even during economic slowdowns. People still need prescriptions, essential health products, and everyday pharmacy items regardless of the economic backdrop.

That provides a level of earnings stability that many other retail-exposed businesses lack.

But Sigma is not just defensive. It also has multiple growth levers. These include store network expansion, private label product growth, international rollout, and ongoing efficiency gains from scale.

I think this combination is powerful. It means investors are not just buying stability, but also a long runway for earnings growth.

Valuation is not cheap, but may be justified

Of course, there is a catch with this ASX 200 stock

Sigma is not what most investors would describe as cheap.

According to CommSec, the company is expected to generate earnings per share of 6.2 cents in FY26 and 7.1 cents in FY27. That places the stock on a relatively high price-to-earnings (P/E) multiple of approximately 42x and 36x, even after the recent share price decline.

But quality businesses often trade at a premium for a reason.

Sigma’s scale, brand exposure through Chemist Warehouse, defensive earnings profile, and synergy potential arguably justify a higher valuation than a typical distributor or retailer.

I think the recent pullback may simply reflect broader market conditions or profit-taking after a strong run, rather than any deterioration in fundamentals.

Does the fall make it a no-brainer buy?

For me, the key question is whether the long-term story has changed.

Right now, there is little evidence to suggest it has. The business continues to deliver strong growth, integration is on track, and the underlying industry dynamics remain favourable.

Yes, the valuation still requires some belief in future growth. But with multiple tailwinds and a proven retail model, that belief does not seem misplaced.

Foolish Takeaway

Sigma Healthcare’s share price weakness is likely to grab attention, but the fundamentals tell a different story.

This is now a scaled, defensive healthcare business with strong growth drivers, a powerful retail brand, and meaningful synergies yet to be realised. While it is not conventionally cheap, high-quality companies rarely are.

For investors willing to look beyond short-term share price movements, I think the recent pullback could be an attractive opportunity to buy a business that is stronger and has long-term potential.

The post Does this ASX 200 stock’s fall make it a no-brainer buy? appeared first on The Motley Fool Australia.

More reading

• ASX 200 healthcare shares down 33% in a year as heavyweights hit multi-year lows
• 3 ASX shares to buy for magnificent long-term growth!
• I’m listening to Warren Buffett and loading up on cheap ASX shares
• 2 top ASX shares I’d buy today amid falling prices
• Why buying ASX shares in March could supercharge your wealth

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.